Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | FYN | P06241 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | AHR | P35869 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29592477 | 0.76 | ADRA2B (0.33) | — | |
| SCHEMBL3124235 | 0.76 | ADRA2B (0.33) | — | |
| SCHEMBL13899918 | 0.74 | HPRT1 (0.52) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL13899922 | 0.72 | CYP1A2 (0.47) | ERBB2CYP1A2FYNMAOAACHE | |
| SCHEMBL13588215 | 0.69 | CYP1A2 (0.38) | CYP1A2 | |
| SCHEMBL194724 | 0.69 | HTR1B (0.46) | CYP1A2 | |
| SCHEMBL29790427 | 0.69 | HTR1B (0.46) | CYP1A2 | |
| SCHEMBL4838631 | 0.68 | ADRA2B (0.33) | — | |
| SCHEMBL29592315 | 0.68 | IMPDH2 (0.38) | CYP1A2 | |
| SCHEMBL17063035 | 0.68 | IMPDH2 (0.38) | CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394482-B2 | Polymerizable compound, polymerizable composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-9394482-B2 | Polymerizable compound, polymerizable composition and liquid crystal display device | JNC CORPORATION (JP) | 2016-07-19 | — | — | US | disclosed |
| US-20150102259-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
| US-20150102259-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | JNC CORPORATION (JP) | 2015-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150102259-A1 | POLYMERIZABLE COMPOUND, POLYMERIZABLE COMPOSITION AND LIQUID CRYSTAL DISPLAY DEVICE | NCAPD3, LEO1, PYM1 | ERBB2 1962/4885CYP1A2 175/4885FYN 533/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.